Empower the Heart of Patients with Terminal Cancer using Cardiac Medicines Trial

niversitätsklinikum Essen0 个研究点目标入组 72 人开始时间: 2022年1月4日最近更新: 2024年3月18日

适应症

试验速览

暂无简介。

•1. Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the subject.
•2. Age = 18 years
•3. Male or female subject with solid cancer in UICC stage 4 (in palliative care).
•4. Three-six months expected survival (minimum 1 month) as assessed according to local standards.
•5. Patients under optimised pain management.
•6. Patients must be able to swallow tablets.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 22

•1. Previous participation in this trial. Participation is defined as randomised.
•2. Ongoing haemodialysis
•3. Patients currently on intravenous iron
•4. Acute sepsis with at least 2 points at the quick sequential organ failure assessment (qSOFA) score. The use of i.v.-antibiotics is permitted in patients with a lower qSOFA score.
•5.Ongoing acute exacerbation of chronic obstructive pulmonary disease (COPD)
•6. Acute ST elevation myocardial infarction (STEMI) or severe pulmonary embolism (PE) or severe deep vein thrombosis (DVT) (currently or in last 4 weeks)
•7. Current uncontrolled cerebral metastasis
•8. Impaired neurological status, precluding the ability to walk
•9. Unable or unwilling to give written informed consent
•10. Participation in other interventional trials using investigational products in randomised settings within the last 30 days

发起方

niversitätsklinikum Essen